Frazier Management 13F-HR Quarterly holdings report by institutional manager

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number:		3235-0006
Expires:	Oct 31, 2018
Estimated average burden
hours per response:		23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8
			VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x$1000)	PRN AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
ALPINE IMMUNE SCIENCES INC	COM	02083G100	25,509	2,199,011	SH		SOLE		2,199,011	0	0
AMICUS THERAPEUTICS INC	COM	03152W109	39,208	2,600,014	SH		SOLE		2,600,014	0	0
ANAPTYSBIO INC	COM	032724106	128,911	3,688,448	SH		SOLE		3,688,448	0	0
CIDARA THERAPEUTICS INC	COM	171757107	10,629	1,312,258	SH		SOLE		1,312,258	0	0
COLLEGIUM PHARMACEUTICAL INC	COM	19459J104	19,798	1,887,332	SH		SOLE		1,887,332	0	0
IGNYTA INC	COM	451731103	26,844	2,173,593	SH		SOLE		2,173,593	0	0
IOVANCE BIOTHERAPEUTICS INC	COM	462260100	16,960	2,188,331	SH		SOLE		2,188,331	0	0
SIERRA ONCOLOGY INC	COM	82640U107	12,574	8,112,121	SH		SOLE		8,112,121	0	0